NEW YORK, NY/ACCESSWIRE/March 11, 2022/ Klein Law Firm announces that class action lawsuits have been filed on behalf of shareholders of the following companies. There is no cost to participate in the costume. If you have suffered a claim, you have until the principal plaintiff’s deadline to ask the court to name you as the principal plaintiff.
FirstCash, Inc. (NASDAQ: FCFS)
This lawsuit is on behalf of all persons who purchased shares of FirstCash common stock between February 1, 2018 and November 12, 2021, both dates inclusive.
Lead Applicant Deadline: March 15, 2022
The Complaint alleges that during the Class Period, FirstCash, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) FirstCash made more than 3,600 loans to more than 1,000 active duty military personnel and their families at usurious interest rates in excess of 36% – and often in excess of 200% – in violation of the Military Lending Act (“MLA”) and Consent Order that Cash America entered into with the Consumer Financial Protection Bureau (the “Order”); (b) FirstCash failed to implement the remedies imposed by the order; (c) FirstCash’s financial results were largely the product of the Company’s breaches of the MRLA and the Order; and (d) as a result of the foregoing, FirstCash was exposed to material undisclosed risk of legal, reputational and financial harm if the Company’s violations of the AMLA and Ordinance were ever publicly disclosed.
Learn more about your recoverable losses in FCFS: https://www.kleinstocklaw.com/pslra-1/firstcash-inc-loss-submission-form?id=24607&from=1
New Oriental Education & Technology Group Inc. (NYSE:EDU)
Class period: April 24, 2018 – July 22, 2021
Lead Applicant Deadline: April 5, 2022
The Complaint alleges that throughout the Class Period, New Oriental Education & Technology Group Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) revenues and growth operations of New Oriental were the result of deceptive marketing tactics and abuse of business practices that flouted Chinese regulations and policies and placed the Company at extreme risk of more drastic measures being imposed on the Company; (b) New Oriental had engaged in deceptive and fraudulent advertising practices, including providing false and misleading discount information designed to conceal the true cost of the Company’s programs from its customers; (c) New Oriental falsified teachers’ qualifications and experience in order to attract clients and increase student enrollment; (d) New Oriental had defied previous government warnings against linking school enrollment to the provision of private tutoring services; (e) as a result of the foregoing, New Oriental was subject to an undisclosed tail risk of adverse enforcement actions, regulatory fines and penalties, and the imposition of new rules and regulations adverse to the business and interests of the Company; and (f) as a result of the foregoing, defendants’ positive statements regarding the Company’s business, operations and prospects were materially misleading and lacked reasonable and factual basis.
Learn more about your recoverable losses in EDU: https://www.kleinstocklaw.com/pslra-1/new-oriental-education-technology-group-inc-loss-submission-form?id=24607&from=1
Cabaletta Bio, Inc. (NASDAQ: CABA)
This lawsuit is on behalf of persons and entities that have purchased or otherwise acquired: (a) common stock of Cabaletta pursuant to and/or documents issued in connection with the Company’s completed initial public offering on or around October 24, 2019; and/or (b) Cabaletta securities between October 24, 2019 and December 13, 2021, both dates inclusive.
Lead Applicant Deadline: April 29, 2022
Throughout the Class Period, Cabaletta Bio, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) key Phase 1 clinical trial data reported that Cabaletta’s lead product candidate, DSG3-CAART, among other things, worsened some participants’ disease activity scores and required additional systemic medication to improve disease activity after DSG3 infusion -CAART; (ii) as a result, DSG3-CAART was not as effective as the Company had represented it to investors; (iii) therefore, the Company had exaggerated the clinical and/or commercial prospects of DSG3-CAART; and (iv) as a result, the Company’s public statements were materially false and misleading at all material times.
Find out about your recoverable losses in CABA: https://www.kleinstocklaw.com/pslra-1/cabaletta-bio-inc-loss-submission-form?id=24607&from=1
Your ability to participate in any collection does not require you to serve as the lead plaintiff. If you have suffered a loss during the course period and would like further information, please contact J. Klein, Esq. by phone at 212-616-4899 or visit the web pages provided.
J. Klein, Esq. represents investors and participates in securities litigation involving financial fraud across the country. Lawyer advertisement. Prior results do not guarantee similar results.
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
THE SOURCE : Klein law firm
See the source version on accesswire.com: